ProMetic Life Sciences Inc. to Present at Biotech Showcase 2010

MONTREAL, QUEBEC--(Marketwire - January 07, 2010) - ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) today announced that Mr. Pierre Laurin, President and Chief Executive Officer, will be giving a corporate presentation at the upcoming Biotech Showcase 2010 conference. Mr. Laurin will be speaking on Tuesday, January 12, 2010 at 08:40 (PST) in the Crystal Lounge of the Marines’ Memorial Club & Hotel, 609 Sutter Street, San Francisco, California, USA. The presentation will include information on the following subjects:

- Revenue guidance for 2010

- Validation of PBI-1402’s regulatory pathway with the Food and Drug Administration

- P-Capt® prion capture filter in the United Kingdom

- Latest collaborative agreement with Abraxis BioScience, Inc.

A summary of the presentation will be provided by press release following the conference. In addition, the presentation will be available on ProMetic’s web site in the “Special Highlights” - http://www.prometic.com/en/index.php and in the “Events” section - http://www.prometic.com/en/news-events/events.php .

About Biotech Showcase 2010

Biotech Showcase 2010 (http://www.ebdgroup.com/bts/index.htm), which is focused on biotechnology, provides private and public presenting companies an opportunity to present to an audience of investors and biopharmaceutical business development executives.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic “drug-like” protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe, Asia and in the Middle-East.